1. Coyne KS, Sexton CC, Thompson CL et al. The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the Epidemiology of LUTS (EpiLUTS) study. BJU Int 2009; 104: 352–60.
2. Coyne KS, Sexton CC, Bell JA et al. The prevalence of lower urinary tract symptoms (LUTS) and overactive bladder (OAB) by racial/ethnic group and age: Results from OAB-POLL. Neurourol Urodyn 2013; 32: 230–7.
3. Platz EA, Joshu CE, Mondul AM et al. Incidence and progression of lower urinary tract symptoms in a large prospective cohort of United States men. J Urol 2012; 188: 496–501.
4. Prins J, Blanker MH, Bohnen AM et al. Prevalence of erectile dysfunction: a systematic review of population-based studies. Int J Impot Res 2002; 14: 422–32.
5. Pushkar DY, Kamalov AA, Al-Shukri SH et al. An epidemiological study of the prevalence of erectile dysfunction in the Russian Federation. Russ Med J 2012; p. 112.
6. Kubin M, Wagner G, Fugl-Meyer AR. Epidemiology of erectile dysfunction. Int J Impot Res 2003; 15: 63–71.
7. Seftel AD, De la Rosette J, Birt J Porter V et al. Coexisting lower urinary tract symptoms and erectile dysfunction: a systematic review of epidemiological data. Int J Clin Pract 2013; 67: 32–45.
8. Ponholzer A, Temml C, Obermayr R, Madersbacher S. Association between lower urinary tract symptoms and erectile dysfunction. Urology 2004; 64: 772–6.
9. Braun MH, Sommer F, Haupt G et al. Lower urinary tract symptoms and erectile dysfunction: comorbidity or typical «aging male» symptoms? Results of the «Cologne Male Survey». Eur Urol 2003; 44: 588–94.
10. Rosen R, Altwein J, Boyle P et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 2003; 44: 637–49.
11. Oelke M, Bachmann A, Descazeaud A et al. M. Guidelines on the management of male lower urinary tract symptoms (LUTS), incl. benign prostatic obstruction (BPO). European Association of Urology 2013. Available from http://www.uroweb.org/gls/pdf/
13_Male_LUTS_LR.pdf
12. McVary KT, Roehrborn CG, Avins AL et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol 2011; 185: 1793–803.
13. Cornu JN, Cussenot O, Haab F, Lukacs B. A widespread population study of actual medical management of lower urinary tract symptoms related to benign prostatic hyperplasia across Europe and beyond official clinical guidelines. Eur Urol 2010; 58: 450–6.
14. Govorov AV, Pushkar DY. The improvement of continence recovery by tadalafil after bilateral nerve-sparing robot-assisted radical prostatectomy: a randomized study with 1 year follow-up. Eur Urol Suppl 2012; 11: e564.
15. PRNewswire (Oct. 30, 2012). European Commission approves Cialis® (tadalafil) tablets for the treatment of the signs and symptoms of benign prostatic hyperplasia. Available from http://newsroom.lilly.com/releasedetail.cfm?releaseid=717071. Accessed April 4, 2013
16. Giuliano F, Ückert S, Maggi M et al. The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Eur Urol 2013; 63: 506–16.
17. McVary KT. Erectile dysfunction and lower urinary tract symptoms secondary to BPH. Eur Urol 2005; 47: 838–45.
18. Gacci M, Eardley I, Giuliano F et al. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 2011; 60: 809–25.
19. Andersson KE, De Groat WC, McVary KT et al. Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: Pathophysiology and mechanism(s) of action. Neurourol Urodyn 2011; 30: 292–301.
20. Kim SD, Park JW. Role of phosphodiesterase type 5 inhibitor on benignprostatic hyperplasia/lower urinary tract symptoms. Korean J Androl 2011; 29: 91–100.
21. Yassin A, Saad F, Hoesl CE et al. Alpha-adrenoceptors are a common denominator in the pathophysiology of erectile function and BPH/LUTS-implications for clinical practice. Andrologia 2006; 38: 1–12.
22. Uckert S, Sormes M, Kedia G et al. Effects of phosphodiesterase inhibitors on tension induced by norepinephrine and accumulation of cyclic nucleotides in isolated human prostatic tissue. Urology 2008; 71: 526–30.
23. Kedia GT, Sonnenberg JE, Kuczyk MA, Uckert S. In vitro functional responses of isolated human urethral tissue to phosphodiesterase (PDE) inhibitors (Abstract 931). Eur Urol Suppl 2011; 10: 291–2.
24. Filippi S, Morelli A, Sandner P et al. Characterization and functional role of androgen-dependent PDE5 activity in the bladder. Endocrinology 2007; 148: 1019–29.
25. Morelli A, Sarchielli E, Comeglio P et al. Phosphodiesterase type 5 expression in human and rat lower urinary tract tissues and the effect of tadalafil on prostate gland oxygenation in spontaneously hypertensive rats. J Sex Med 2011; 8: 2746–60.
26. Azadzoi KM, Babayan RK, Kozlowski R, Siroky MB. Chronic ischemia increases prostatic smooth muscle contraction in the rabbit.
 J Urol 2003; 170: 659–63.
27. Bertolotto M, Trincia E, Zappetti R et al. Effect of tadalafil on prostate haemodynamics: preliminary evaluation with contrast-enhanced US. Radiol Med 2009; 114: 1106–14.
28. Behr-Roussel D, Oger S, Caisey S et al. Vardenafil decreases bladder afferent nerve activity in unanesthetized, decerebrate, spinal cordinjured rats. Eur Urol 2011; 59: 272–9.
29. Minagawa T, Aizawa N, Igawa Y, Wyndaele JJ. Inhibitory effects of phosphodiesterase 5 inhibitor, tadalafil, on mechanosensitive bladder afferent nerve activities of the rat, and on acrolein-induced hyperactivity of these nerves. BJU Int 2012; 110: E259–66.
30. Gacci M, Salvi M, Sebastianelli A et al. The use of a single daily dose of tadalafil to treat signs and symptoms of benign prostatic hyperplasia and erectile dysfunction. Res Rep Urol 2013; 5: 99–111.
31. Gacci M, Corona G, Salvi M et al. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with a-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 2012; 61: 994–1003.
32. Martínez-Salamanca JI, Carballido J et al. Phosphodiesterase
 type 5 inhibitors in the management of non-neurogenic male lower urinary tract symptoms: critical analysis of current evidence. Eur Urol 2011; 60: 527–35.
33. Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol 2008; 180: 1228–4.
34. American Urological Association (AUA). Guideline on the management of benign prostatic hyperplasia (BPH). AUA Web site. http://www. auanet.org/content/guidelines-and-quality-care/clinical-guidelines/ main-reports/bph-management/chap_1_Guideline Management of (BPH).pdf. Updated 2010. Accessed July 20, 
2011
35. Broderick GA, Brock GB, Roehrborn CG et al. Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia in men with or without erectile dysfunction. Urology 2010;75:1452-8.
36. Donatucci CF, Brock GB, Goldfischer ER et al. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a 1 year open-label extension study. BJU Int 2011; 107: 1110–6.
37. Porst H, Kim ED, Casabé AR et al. LVHJ study team. Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of a multinational randomized, double-blind, placebo-controlled trial. Eur Urol 2011; 60: 1105–13.
38. Egerdie RB, Auerbach S, Roehrborn et al. Tadalafil 2,5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study. J Sex Med 2012; 9: 271–81.
39. Porst H, Oelke M, Goldfischer ER et al. Efficacy and safety of tadalafil 5 mg once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: subgroup analyses of pooled data from 4 multinational, randomized, placebo-controlled clinical studies. Urology 2013; 82 (3): 667–73.
40. Porst H, Roehrborn CG, Secrest RJ et al. Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia and on erectile dysfunction in sexually active men with both conditions: analyses of pooled data from four randomized, placebo-controlled tadalafil clinical studies. J Sex Med 2013; doi: 10.1111/jsm.12212.
41. Brock G, Broderick G, Roehrborn CG et al. Tadalafil once daily in the treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in men without erectile dysfunction. BJU Int 2013; doi: 10.1111/bju.12251.
42. Oelke M, Giuliano F, Mirone V et al. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. Eur Urol 2012; 61: 917–25.
43. Giuliano F, Oelke M, Jungwirth A et al. Tadalafil once daily improves ejaculatory function, erectile function, and sexual satisfaction in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia and erectile dysfunction: results from a randomized, placebo- and tamsulosin-controlled, 12-week double-blind study. J Sex Med 2013; 10: 857–65.
44. Kumar S, Kondareddy C, Ganesamoni R et al. Randomized controlled trial to assess the efficacy of the combination therapy of alfuzosin and tadalafil in patients with lower urinary tract symptoms due to benign prostatic hyperplasia. LUTS: Lower urinary tract symptoms. 2013; doi: 10.1111/luts.12016.
45. Regadas RP, Reges R, Cerqueira JB et al. Urodynamic effects of the combination of tamsulosin and daily tadalafil in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: a randomized, placebo-controlled clinical trial. Int Urol Nephrol 2013; 45: 39–43.
46. Bechara A, Romano S, Casabé A et al. Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS/BPH. Pilot study. J Sex Med 2008; 5 (9): 2170–8.
47. CIALISR (tadalafil) Prescribing Information. Eli Lilly and Company. Revised October 2011.
48. Miller MS. Role of phosphodiesterase type 5 inhibitors for lower urinary tract symptoms. Ann Pharmacother 2013; 47: 278–83.
49. Roehrborn CG, Casabe AR, Da Pozzo LF et al. Effects of the once-daily coadministration of tadalafil with finasteride for 6 months: 
A randomized, placebo-controlled study in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. 28th Annual European Association of Urology (EAU) Congress; Milan, Italy; Mar 15–19, 2013. Poster 1096.
50. Takeda M, Nishizawa O, Imaoka T et al. LVIA: Tadalafil for the treatment of lower urinary tract symptoms in Japanese men with benign prostatic hyperplasia; results from a 12-week placebo-controlled dose-finding study and a 42-week open-label extension. LUTS 2012; 3: 110–9.
51. Dmochowski R, Roehrborn C, Klise S et al. Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial. J Urol 2010; 183: 1092–7.
52. Goldfischer E, Kowalczyk JJ, Clark WR et al. Hemodynamic effects of once-daily tadalafil in men with signs and symptoms of benign prostatic hyperplasia on concomitant a1-adrenergic antagonist therapy: results of a multicenter randomized, double-blind, placebo-controlled trial. Urology 2012; 79: 875–82.
53. Casabé A, Roehrborn CG, Da Pozzo LF et al. Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia. J Urol 2014; 191 (3): 727–33.

А.В.Говоров, Г.Р.Касян, А.О.Васильев, Д.Ю.Пушкарь

Кафедра урологии ГБОУ ВПО Московский государственный медико-стоматологический университет им. А.И.Евдокимова Минздрава России